Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications

DOI to cite this document:: 10.5283/epub.51539

Schilling, Hannah-Lou ; Glehr, Gunther

; Kapinsky, Michael ; Ahrens, Norbert

; Riquelme, Paloma

; Cordero, Laura ; Bitterer, Florian ; Schlitt, Hans J.

; Geissler, Edward K.

; Haferkamp, Sebastian ; Hutchinson, James A.

; Kronenberg, Katharina

License: Creative Commons Attribution No Derivatives 4.0
PDF - Published Version
(6MB) - Repository staff only

Date of publication of this fulltext: 27 Jan 2022 16:57

Alternative links to fulltext:DOI Publisher

Details

Export bibliographical data

Abstract

Treatment of advanced melanoma with combined immune checkpoint inhibitor (ICI) therapy is complicated in up to 50% of cases by immune-related adverse events (irAE) that commonly include hepatitis, colitis and skin reactions. We previously reported that pre-therapy expansion of cytomegalovirus (CMV)-reactive CD4+ effector memory T cells (TEM) predicts ICI-related hepatitis in a subset of patients ...